Zoetis Inc. (NYSE:ZTS) EVP Sells $110,840.00 in Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president now directly owns 15,129 shares of the company’s stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Roxanne Lagano also recently made the following trade(s):

• On Monday, March 10th, Roxanne Lagano sold 326 shares of Zoetis stock. The shares were sold at an average price of $170.00, for a total value of $55,420.00.

Zoetis Stock Up 0.9%

NYSE:ZTS opened at $170.15 on Friday. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a 50-day moving average of $157.41 and a 200 day moving average of $164.37. The firm has a market cap of $75.75 billion, a PE ratio of 31.11, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the prior year, the company earned $1.38 EPS. The company’s revenue was up 1.4% compared to the same quarter last year. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.18%. Zoetis’s dividend payout ratio is currently 35.91%.

Institutional Trading of Zoetis

A number of hedge funds have recently bought and sold shares of the stock. Callahan Advisors LLC lifted its stake in shares of Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares during the last quarter. CIBC Asset Management Inc lifted its position in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after acquiring an additional 46,050 shares during the last quarter. Schroder Investment Management Group lifted its position in Zoetis by 2.6% during the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock valued at $40,036,000 after acquiring an additional 6,169 shares during the last quarter. Vanguard Group Inc. lifted its position in Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after acquiring an additional 120,158 shares during the last quarter. Finally, Alberta Investment Management Corp lifted its position in Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after acquiring an additional 28,700 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Piper Sandler boosted their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, May 12th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.